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Abstract 
PCSK1 is a serine protease involved in the 
proteolytic processing of a variety of protein 
precursors mainly neuropeptides and prohormones. 
In 1991, PC1/3; also known as PCSK1, PC1, PC3, 
and SPC3 was identified at the same time by two 
laboratories separately. The human and mouse 
PCSK1 genes are localized on chromosomes 5 and 
13, respectively. The cleavage of these protein 
precursors is required for the mediation of their 
functions including the regulation of glucose 
homeostasis and food intake. The PCSK1 substrates 
that regulate these functions include proinsulin, 
proglucagon, proghrelin and proopiomelanocortin 
and others. PCSK1 polymorphisms were associated 
with risk of obesity and with various endocrine 
disorders. PCSK1 is also involved in the regulation 
of macrophage activation and cytokine secretion. 
The inhibition of PCSK1 activity was proposed to 
reverse the macrophage phenotype from an M2-like 
to an M1-like phenotype. PCSK1 is highly expressed 
in breast cancers and in neuroendocrine tumors 
including carcinoid tumors. The expression of this 
protease at the RNA and protein levels is also 
increased in liver colorectal metastasis, suggesting 
PCSK1 activity in tumorigenesis, however the 
evidence of PCSK1 roles in these cancers and 
probably others remain to be defined. 
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Figure 1:  Genomic organization of PCSK1. 
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Description 
The PCSK1 gene is located on chromosome 5q15-
21 in humans, and chromosome 13c in the mouse 
(Seidah NG et al. 1991a, Seidah NG et al. 1991b). 
The promoter of this gene contains cAMP-response 
elements (CRE-1 and CRE-2). Transcription factors 
such as cAMP-responsive element-binding protein 1 
( CREB1) and Activating Transcription Factor 1 (  
 
ATF1) that can transactivate the PCSK1 promoter 
(Jansen E et al, 1997, Espinosa VP et al, 2008). 
Transcription 
The DNA sequence of PCSK1contains 14 exons and 
the transcript length of 5068 bps is translated to a 753 
residues protein. 4 spliced variants of PCSK1 are 
identified (splice variants) that code for 3 protein 
isoforms of 753 aa, 706 aa and 157 aa in length, 
respectively (M_000439, NM_001177875). 
Protein 
 
Figure 2: Diagram representing the protein structure of PCSK1.  PCSK1 is a multi-domain serine proteinase 
consisting of a signal peptide followed by prosegment, catalytic, middle, and cytoplasmic domain. The P domain 
just after the catalytic domain is required for the stabilization of the catalytic domain. The C-terminal domain is 
involved in the routing of PC1/3 to the secretory granules. 
Description 
PCSK1 is the third member of the proprotein 
convertase Subtilisin/Kexin-like family that was 
cloned from mammalian organisms, after furin and 
PC2 (Seidah NG et al. 1991, Smeekens SP et al, 
1991, reviewed in Scamuffa N et al, 2006). The 
domain structure of PCSK1 precursor consists of 
four domains that include a prodomain (or 
prosegment), a catalytic domain, a P domain, and a 
carboxy-terminal domain (Figure 2). The propeptide 
domain is essential for the appropriate protein 
folding and exit from the endoplasmic reticulum 
(ER) of PCSK1 (Creemers JW1 et al, 1995). The 
catalytic domain is highly conserved among various 
species. Similar to the other members of the 
subtilisin superfamily the amino acids Asp, His, and 
Ser form the catalytic triad. The P domain presents a 
key role in the regulation of the PCSK1 activity 
through calcium and pH modulation (Zhou A1 et al, 
1998). The carboxy-terminal domain is mainly 
involved in PCSK1 sorting into secretory granules 
(Dikeakos JD et al. 2009). 
After the production of PCSK1 preproform in the 
endoplasmic reticulum and removal of its signal 
peptide, the 94kDa precursor of PCSK1 activation 
occurs after both N-and C-terminal domains 
cleavages. The 94kDa precursor undergoes an initial 
autocatalytic processing of its prosegment 
(prodomain). After protein scaffold and N-
glycosylation, proPCSK1 exits the ER and sorts to 
the trans-Golgi network. In the early compartment, 
proPCSK1 is sulfated on its sugar residues. Lately 
during progression to the mildly acidic environment, 
an autocatalytic cleavage occurs to remove the 
prodomain and generates a 87kDa active PCSK1 
form (reviewed in Ramos-Molina B et al , 2016 and 
Stijnen P et al 2016). The cleavage of proPCSK1 that 
generates the 87 kDa PCSK1 is calcium-independent 
and occurs at a neutral pH. PCSK1 is sorted after to 
immature secretory granules where is activated by a 
cleavages at the C-terminal area and generates the 74 
and 66kDa active forms. The active forms are than  
 
accumulated in dense-core secretory granules prior 
secretion. 
Expression 
PCSK1 is expressed in the neuroendocrine system 
such as brain, adrenal glands and in endocrine cells 
of the small intestine (reviewed in Ramos-Molina B 
et al , 2016 and Stijnen P et al 2016). Weak 
expression of PCSK1 is detected in adipocytes, α-
cells of the pancreatic islets and certain types of 
immune cells. In brain, PC1 is mainly expressed in 
the hypothalamus (Dong W et al , 1997), but it is also 
found in cerebral cortex (Figure 3), hippocampus, 
and cerebellum (Billova S1, ET AL , 2007, Schäfer 
MK1, et al 1993). PC1/3 is also expressed in the 
adrenal medulla, pituitary, thyroid gland (Scopsi L et 
al. 1995, Day R ET AL 1992), endocrine pancreas 
(β-cells), liver and small intestine; including L and K 
cells (Tanaka S ET AL 1996). At low levels, PC1/3 
was also detected in adipocytes (Min SYet al, 2016), 
in pancreatic islets (Itoh Y1, et al 1996), and in 
certain types of immune cells (LaMendolaet al 1997, 
Vindrola O et al 1994). 
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Localisation 
In neuroendocrine cells, PCSK1 is mainly localized 
to the secretion granules and traffics within the 
regulated secretory pathway (Hornby PJ et al 1993, 
Malide D et al 1995). In macrophages PC1/3 is 
retained at the TGN as a pool that traffics to LAMP- 
related vesicles. PC1 vesicules are mostly detected 
during macrophages activation (Gagnon H et al, 
2013)  
 
Example of PCSK1 expression in the cerebral cortex and liver.  Shown are overviews of stained tissues 
(circle) with high magnification of representative region (square). Adapted from Protein Atlas database. 
 
Function 
PCSK1 cleaves protein precursors at the consensus 
motif (K/R)-Xn-(K/R)↓, with n=0, 2, 4 or 6, and 
X=any amino acids except Cys, to release mature 
proteins. PCSK1 favors cleavage after K/R motif, 
but is also able to cleave after other dibasic residues. 
PCSK1 often collaborates with PCSK2 to cleave 
substrates, such as neuropeptides and peptide 
hormones and its activity can be inhibited by the 
endogenous inhibitor proSAAS. PC1/3 gene 
disruption results in various developmental 
abnormalities' (reviewed in Ramos-Molina B et al , 
2016 and Stijnen P et al 2016) and PC1/3 null mice 
exhibit growth retardation (reviewed in Scamuffa N 
et al, 2006). The adult mutant mice are 60% of the 
normal size and show similarities with mice having 
mutant growth hormone releasing hormone (GHRH) 
receptor (GHRHR). Further analysis indicated that 
insulin-like growth factor-1 (IGF1) and GHRH 
levels were significantly decreased in  
 
these mice; that may explain the observed growth 
retardation. PCSK1 null mice process normally 
pituitary POMC to ACTH and have normal levels of 
blood corticosterone. Like PCSK2 null mice, PCSK1 
null mice also develop hyperproinsulinemia. These 
mice maintain normal glucose (Glc) tolerance in 
response to injection of glucose, suggesting that their 
hyperproinsulinemia does not impair their glucose 
homeostasis. Previously, Jackson et al. (reviewed in 
Scamuffa N et al, 2006) reported a human case of 
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PC1/3 deficiency. The latter is due to PCSK1 gene 
mutation that prevents activation and secretion of 
proPC1/3 from the endoplasmic reticulum. The 
patient showed neonatal obesity. Subsequent studies 
revealed the presence of various endocrine defects, 
including the presence of very high circulating levels 
of proinsulin and multiple forms of partially 
processed POMC [ACTH precursors intermediate], 
low-serum estradiol, follicle-stimulating hormone, 
and LH. In 2003, another PCSK1 deficiency female 
subject was reported. In addition to the shared 
phenotypes with the previous subject, this female 
infant presented severe diarrhea, which started on the 
third postnatal day. Metabolic studies revealed a 
defect in the absorption of monosaccharides and fat, 
revealing the role of PC1/3 in the small intestinal 
absorptive function. Although the phenotypes of the 
PCSK1 null mice differ from those observed in these 
patients (PCSK1 null mice are not obese), the 
findings confirmed the importance of PCSK1 as a 
key neuroendocrine convertase (reviewed in Ramos-
Molina B et al , 2016 and Stijnen P et al 2016). 
Homology 
An important paralog of this gene is PCSK2. 
Analysis of PCSK1 structure revealed that PCSK1 
catalytic domain present a low percentage of 
homology with those of the other PCs (only 39% 
between PCSK1 and FURIN). The PCSK1 
prodomain is formed by 83 residues and is highly 
conserved between orthologs (∼80% of sequence 
identity), although is not well conserved among 
paralogs of the convertase family (∼30-40%). The 
catalytic domain of PC1/3 is formed by 343 residues 
and is the most conserved region among proproteine 
convertases family members, with 50-60% sequence 
similarity. The P domain is a well-conserved region 
in PCs of approximately 150 residues and the Arg526-
Arg-Gly-Asp529 (RRGD motif) is crucial for proper 
proPC1/3 processing and sorting to the secretory 
granules (reviewed in Ramos-Molina B et al , 2016 
and Stijnen P et al 2016). The C-terminus of PCSK1 
with 159 aa is involved in the sorting processes to 
the dense core secretory granules, as well as in 
PCSK1 activity and stability ((reviewed in Ramos-
Molina B et al , 2016 and Stijnen P et al 2016). 
Mutations 
Germinal 
Various mutations were reported for human PCSK1 
gene and were associated with various syndromes 
including obesity, malabsorptive diarrhea, 
hypogonadotropic hypogonadism, altered thyroid 
and adrenal function, and impaired regulation of 
plasma glucose levels (reviewed in Ramos-Molina B 
et al , 2016 and Stijnen P et al 2016). 
Implicated in 
Breast cancer 
PC1 is highly elevated in human breast carcinomas 
(Cheng et al.1997). Stable expression of PC1 in 
human breast cancer cells MCF-7 altered their 
growth rate and response to estrogen and anti-
estrogen treatments (Cheng et al. 2001). The use of 
transgenic mouse model revealed that PCSK1 
expression promote normal and neoplastic 
mammary development and growth (Blanchard A et 
al 2009). 
Colon cancer and colon cancer 
metastasis 
PC1 expression and protein cleavage profiles are 
altered in colon cancer and liver colorectal 
metastasis, compared to unaffected and normal liver. 
Active PCSK1 protein is overexpressed in these 
tumors and was found to correlate with the mRNA 
profiles (Tzimas G, et al 2005) 
Neuroendocrine tumors 
High expression of PCSK1 is reported for neural 
and/or endocrine phenotype (Takumi I et al 1998, Jin 
L et al, 1999, Kajiwara H et al. 1999). However the 
role and prognostic value of PCSK1 in endocrine-
related cancers is still unclear. 
Endocrine disorders 
PCSK1 deficiency is a very rare genetic disorder, 
few patient cases have been reported. In human, the 
lack of PCSK1 was reported to be associated with 
several cases of hypogonadotropic and/or 
hypogonadism (O'Rahilly et al, 1995).  Several 
patients showed low serum estradiol, FSH, and LH 
(Jackson R et al 1997, Martèn MG et al 2013, 
Bandsma RH, et al 2013, Wilschanski ET AL 2014, 
Solorzano-Vargas RS et al 2013). 
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